A US drug maker books each sale at list price, then has to estimate how much of that money will go back out: rebates to health plans, chargebacks to wholesalers, Medicaid and Medicare payments, fees and copay help. Those estimates are gross-to-net accruals, and the balance they build up is called a reserve. They can take about half of a brand's gross sales, and the bills that settle them arrive months later.
This guide is for anyone who builds, reviews, signs or audits these reserves: gross-to-net accountants, revenue controllers, government pricing teams, financial planning and analysis (FP&A) teams that track net price, audit liaisons and finance leaders deciding whether to automate the work. No background needed.
Imagine you are the revenue controller at a US drug maker, Northwind Bio, on working day 5 of the third-quarter close: Wednesday, October 7, 2026. Gross sales were $6.84 billion, and your team estimates that $3,566.0 million of that goes back through seven programs. Reserves lock tomorrow at 5:00 pm.
Your accountant's schedule for Crestline Rx, a large pharmacy benefit manager (PBM, a company that runs health plans' drug benefits), says 91,000 units of your drug Veltrimab earned a 41% rebate on the list price of $7,120. That rate came from the 2024 agreement. But on June 24 someone in contracting signed Amendment No. 3, and section 4.2 raises the rebate to 44% from July 1.
Accrual schedule · October 5
Units
91,000
List price
$7,120
Rate used
41.0%
Accrued
$265.7 million
Amendment No. 3 · signed June 24
Section
4.2
Effective
July 1, 2026
Rate in force
44.0%
Owed
$285.1 million
$265.7 million accrued$285.1 million owed91,000 units × $7,120 × 3 points = $19.4 million.
No invoice for those units is due until November. Nobody would see the gap until the bill came, and then it would land in a later quarter as a surprise. You take the contract rate, net revenue moves from $3.27 billion to $3.25 billion, and you sign with the clause in front of you.
Careful accrual work catches the amendment that changed a rate while the quarter it belongs to is still open.
What a drug sale is worth after the rebates: reserves, rules, lags and audits
The programs, the accounting test, the calculations, the data, the errors and the auditors, explained without selling anything. If you are new to pharma revenue accounting, start here.
01 · In plain words
Gross-to-net in plain words: the sale is booked today, and its price is settled months later
Picture a store where every customer pays the sticker price at the register, and months later a different party mails in a claim for part of it back. A health plan claims a rebate because it covered your product well. A wholesaler claims the gap between what it paid you and what a hospital paid it. A state claims the Medicaid rebate the law requires. On the day you make the sale, you know what you charged. You do not yet know what you will keep.
US drug makers live in that store. The list price, called wholesale acquisition cost (WAC), is what the sale is first recorded at. The difference between that gross amount and what the maker keeps is called gross-to-net, often shortened to GTN. Drug Channels Institute estimates that total reductions for brand-name drugs reached $416 billion in 2025.1 Three of the eight large makers it studied disclosed an average discount from list, and those averaged 51.7%.1
Accounting rules do not let a company wait for the bills. Revenue has to be recorded when the product is delivered, at the amount the company expects to keep. So at each quarter's close, a small team estimates every deduction, program by program. Each estimate is an accrual, and the running balance of what is owed is a reserve. Teams use the words almost interchangeably. Auditors call these amounts variable consideration.
Then the real bills arrive, weeks or quarters later. When a bill differs from the estimate, the difference is a true-up, and it moves the revenue of whichever quarter is open at the time. Done well, a true-up is small and explained. Done badly, last quarter's mistake appears in this quarter's results, and investors and auditors ask why.
One Crestline rebate, from signed amendment to the true-up that never happened
The contract changesOn June 24, Northwind Bio signs Amendment No. 3 with Crestline Rx: 44% instead of 41% on exclusive plans from July 1.
The product sellsFrom July to September, 91,000 units on those plans are dispensed. Nothing about the rebate happens at the pharmacy counter.
The quarter closes and the accrual is estimatedBy working day 5 the schedule is rebuilt and checked. This is where the $19.4 million is caught, or missed.
The controller and the auditor reviewThe rate, the units and the clause go into a signed memo and an answer to the auditor's request.
The bill arrives and settles the reserveThe sample contract has invoices 45 days after quarter end, so mid-November. A right accrual means no true-up.
Step 3 is the subject of this guide. The people, companies and figures in this example are fictional.
Why pharma revenue reserves surprise newcomers: half the sales, late bills, rebates above the price
Half of gross sales can be an estimate
One large maker's 2025 annual report shows $41.3 billion of deductions on $88.1 billion of gross product sales, about 47%.2,3
The bill can come years later
Medicare's inflation rebates reach back to 2022 and 2023, and the federal fact sheet on calendar 2023 Medicare Part B invoices gives its figures as of September 2025.4 A reserve can sit open far longer than the quarter it belongs to.
A rebate can exceed the price
Since January 1, 2024, the Medicaid rebate has no cap at 100% of average manufacturer price.5 KPMG notes this can leave the maker losing money on a unit.6
Spreadsheets still run most of it
At a 2025 industry summit, 66% of poll responses named Excel as the system for the gross-to-net process.7 That is an audience poll with no stated sample size, and it matches KPMG's description of manual models and systems that do not talk to each other.6
Four terms every reserve memo uses: accrual, reserve, true-up, lag
Accrual, or provision
This quarter's estimated deduction for this quarter's sales. It reduces revenue.
Reserve
The balance owed at a date: the opening balance, plus provisions and adjustments, less payments.
True-up
A change to an earlier period's estimate, booked in the period when it is learned.
Lag
The time between a sale and the payment that settles it. Longer lags mean more judgment.
What sits between gross sales and net revenue: from Medicaid rebates to prompt-pay discounts
In shortA gross-to-net bridge steps from gross sales down through each deduction to net revenue. Most makers carry commercial rebates, Medicaid, Medicare, 340B and other chargebacks, fees, copay support, returns and prompt-pay discounts, and each has its own payee, data and clock. At one large maker whose filing we read, Medicaid and Medicare are the largest slice.
In the example, three of seven programs hold more than three-quarters of the deductions
Northwind Bio, third quarter 2026, provision by program, on $6.84 billion of gross sales
Commercial PBM rebates$1.4B
Medicaid rebates$684M
Medicare Part D$612M
340B discounts$318M
Other chargebacks$214M
GPO and distributor fees$176M
Copay assistance$142M
Fictional example from this guide · Total $3,566.0 million, 52.1% of gross. Commercial PBM, Medicaid and Part D are $2,716.0 million, or 76%. A real maker's mix depends on its products and payers.
Show the numbers
Item
Value
Commercial PBM rebates
$1.4B
Medicaid rebates
$684M
Medicare Part D
$612M
340B discounts
$318M
Other chargebacks
$214M
GPO and distributor fees
$176M
Copay assistance
$142M
Deduction
Who receives it
What sets it
Evidence that settles it
Commercial rebates
Pharmacy benefit managers (PBMs, the companies that run a plan's drug benefit) and health plans
The contract and its amendments
PBM invoice and utilization file, after the quarter ends
Medicaid rebates
State Medicaid programs
Statute: unit rebate amount by drug and quarter, plus any supplemental agreement5,8
State invoices, 60 days or more after the quarter5
Medicare Part D discounts
Medicare's discount program for Part D, its prescription drug benefit, through plans
Statute: 10% in initial coverage, 20% in the catastrophic phase, from 20259
Federal program invoices
Medicare negotiated price refunds
Pharmacies, on selected drugs
The negotiated price (maximum fair price, MFP) from January 1, 202610
Claim-level refund notices from the Medicare Transaction Facilitator, the federal go-between for pharmacies and makers11
Medicare inflation rebates
Medicare
Price growth above inflation, Part B and Part D12,4
Federal invoices, then reconciliations
340B discounts
Safety-net hospitals and clinics in the federal 340B drug pricing program, through wholesaler chargebacks
Ceiling price: average manufacturer price less the Medicaid rebate percentage13
Chargeback lines on electronic claims
Other chargebacks
Wholesalers, for the gap between list and contract price
Medicaid and Medicare are the largest slice of that maker's deductions every year
Share of total gross-to-net adjustments, our arithmetic from the annual report
Medicaid and Medicare rebatesChargebacks and cash discountsOther rebates, returns, discounts
2023, $29.9B44.9%30.6%24.6%
2024, $36.9B44.9%31.2%23.9%
2025, $41.3B43.6%34%22.4%
Source2 · From one company's Form 10-K for 2025. The company puts the higher percentage mainly down to the Part D redesign and more sales through government channels. Other makers differ.
Show the numbers
Medicaid and Medicare rebates
Chargebacks and cash discounts
Other rebates, returns, discounts
2023, $29.9B
44.9%
30.6%
24.6%
2024, $36.9B
44.9%
31.2%
23.9%
2025, $41.3B
43.6%
34%
22.4%
Where the amount sits on the balance sheet differs too. The same maker takes chargebacks and cash discounts against receivables, and carries the other deductions as liabilities settled in cash.16 When you compare reserves across companies, check which is which. These shares can also turn quickly: the same maker's table for the third quarter of 2026 works out to about 30% of gross, from about 47% a year earlier, and its 2026 filings put that down mainly to a US list price cut.17
03 · The accounting test
ASC 606 and the "significant reversal" test behind every rebate accrual
In shortUS accounting standard ASC 606 treats rebates and chargebacks as variable consideration: part of the price that can change after the sale. You estimate it with a method that fits, include revenue only to the extent a significant reversal is not probable, and revisit the estimate every reporting date.
Step 1 · Estimate
Pick a method and keep to it
ASC 606 allows the expected value, a probability-weighted amount, or the single most likely amount, better suited to two possible outcomes.18,19 One large maker's report says it uses "an expected value approach" for rebates and discounts.20
Step 2 · Constrain
Keep only what will not reverse
Revenue goes in only "to the extent that it is probable that a significant reversal" will not occur. Probable means likely to occur, and the test weighs both how likely a reversal is and how large it would be.18,21
Step 3 · Update
Re-estimate every close
New information changes the estimate, and the change goes through revenue in the current period. That is the normal true-up.22 Old information that was overlooked is a different matter, as section 09 explains.
Why a brand-new program fails the constraint test faster than an old one
ASC 606 lists factors that raise the risk of a reversal, and says they "include, but are not limited to" those it names.18 Each deduction scores differently against them. Medicaid sits highest, since states decide their formularies (the lists of drugs they prefer) and invoices arrive late. A program with little payment history has "limited predictive value", as the standard puts it, whatever its size.
Medicaid and new Medicare programs carry the most reversal risk under ASC 606's factors
How strongly each factor applies to each deduction, by our reading
LowSomeHighVery high
Outside your influenceLong to resolveWeak historyWide range of amountsMedicaid rebatesVery highVery highSomeHighCommercial PBM rebatesSomeHighSomeHighMedicare negotiated price refundsHighLowVery highSomeMedicare inflation rebatesHighVery highHighHigh340B and other chargebacksSomeLowLowSomeFees and copayLowLowLowSome
Our reading of the sources21,5,11,23 · A judgment for orientation. Your own products and contracts may read differently.
Show the numbers
Outside your influence
Long to resolve
Weak history
Wide range of amounts
Medicaid rebates
Very high
Very high
Some
High
Commercial PBM rebates
Some
High
Some
High
Medicare negotiated price refunds
High
Low
Very high
Some
Medicare inflation rebates
High
Very high
High
High
340B and other chargebacks
Some
Low
Low
Some
Fees and copay
Low
Low
Low
Some
Booking the worst case on purpose is a problem of its own. A deliberately high reserve understates revenue today and releases it later, and the SEC has alleged improper "cookie jar" reserves against a drug maker in the past. Auditors are directed to watch for bias in estimates.24,25
Where the wording comes from. The Codification from the Financial Accounting Standards Board (FASB), the official text of US accounting standards, is licensed. We checked the quotations against FASB's published Accounting Standards Update 2014-09, which added these paragraphs, and against a university accounting site's copy; the method notes also draw on an accounting firm's note. Read the Codification itself, ASC 606-10-32-5 through 32-14, and your own auditors' interpretive guide before setting a policy. Companies reporting under IFRS 15 apply a similar model in different words.
04 · The 2024 to 2028 rule changes
Eight federal changes reaching the gross-to-net bridge between 2024 and 2028
Status as of November 2026
In shortNo federal rule says how to build a reserve, but federal programs now decide much of what goes into one. The Medicaid cap ended, Part D was redesigned, negotiated Medicare prices began, and new models and PBM law are arriving. Each new program starts with little payment history, which is where estimates are hardest to support.
Since 2024, a new federal program has reached the reserve almost every year
Jan 1, 2024Medicaid rebate cap ends
Periods from this date can exceed 100% of average manufacturer price.
Jan 1, 2025Part D Manufacturer Discount Program
10% and 20% replace the coverage gap discount.
Jan 1, 2026First negotiated Medicare prices
Ten drugs, paid as refunds to pharmacies. GENEROUS Medicaid rebates also date from here.
Feb 3, 2026Appropriations act reforms PBM pay
Part D from 2028, employer plans about 30 months after enactment.
Nov 2026Where things stand
GLOBE final and challenged in court, GUARD at the White House budget office, 340B rebate pilot under challenge.
Jan 1, 2027Next 15 negotiated prices; 340B pilot date
GLOBE model is set to start too; its performance period opens April 1, 2027.
Jan 1, 2028Part D PBM pay delinked from drug prices
Flat service fees; rebates passed through to plan sponsors.
The inflation part of the unit rebate is included in full, so a price rise long ago can make the rebate larger than average manufacturer price.5,6
In force for periods from January 1, 2024
Part D Manufacturer Discount Program
The discounted price is 90% or 80% of the negotiated price, by phase, for drugs dispensed from January 1, 2025. Selected drugs are excluded during their negotiated price period.9
In force
Negotiated Medicare prices
The refund notice for a claim starts a "14-day prompt maximum fair price payment window". The default refund is list price less negotiated price, times units.11,33 Best Price, the lowest price the maker gave most buyers in the quarter, "shall be inclusive of the maximum fair price" for a selected drug, so Medicaid can feel it too.5
Ten drugs since January 1, 2026; 15 more January 1, 2027, the day CMS, the federal Medicare and Medicaid agency, lists four of the first ten for removal10
Medicare inflation rebates
Part B rebates owed for calendar 2025 total more than $360 million as of June 2026, and CMS will reconcile them later.12 A calendar 2027 proposed rule issued July 14, 2026; CMS says a final rule follows later this year.4
Invoicing; rule pending
GLOBE and GUARD
CMS test programs, called models, for most-favored-nation rebates in Medicare, tied to prices paid in other countries. GLOBE (Part B) is final at 91 FR 62936 in the Federal Register, effective November 30, 2026, in areas covering about 25% of enrollees.28 PhRMA, the drug makers' trade group, sued in federal court in Washington, D.C., on October 7, 2026, and we found no ruling by November 3.32 GUARD (Part D) was still under review at the White House budget office on November 3, 2026.31
GLOBE final, challenged in court; GUARD not published
GENEROUS
A voluntary Medicaid model of supplemental rebates set from prices paid abroad, retroactive to January 1, 2026.34,26 Retroactive terms mean accruing before an agreement's first invoice.
Launched January 2026; CMS's page, modified October 14, 2026, lists it as announced, with state applications due September 30
340B rebate pilot
A federal court blocked the first version, and it was vacated February 10, 2026. The revised notice from HRSA, the federal agency that runs 340B, sets January 1, 2027 for drugs selected for 2026 and 2027, "less than 5.5% of total 340B sales". Hospitals sued October 9, 2026; a House bill would delay it through 2028.29,30,35
No ruling or vote found November 3, 2026; docket not read
PBM law and FTC orders
Sections 6224 and 6702 of the February 2026 appropriations act change how PBMs are paid. CMS proposed rules on October 20, 2026, with comments due December 15.27,36 Federal Trade Commission orders with two PBMs remain proposed.37 Expect amendments, and every amendment is a rate to check.
Part D from January 1, 2028
On Medicare forecasting, the audience at a 2025 summit was asked which part of the Inflation Reduction Act, the 2022 law behind Medicare negotiation and inflation rebates, was hardest to forecast. 60% answered "everything, all at once".7 It was an audience poll with no stated sample size.
Which quality rules do not apply. Reserves are financial reporting. GxP (the good-practice rules for drug quality), 21 CFR Part 11 and EU Annex 11 cover regulated development and manufacturing records. FDA's Computer Software Assurance guidance covers software in device production and quality systems.38 Draft EU GMP Annex 22 is still a draft and concerns critical GMP applications.39 None of them governs a rebate accrual. The controls that matter here are internal control over financial reporting (the checks that keep reported numbers reliable) and the audit standards in section 09.40
05 · Feeds and payment lags
The 852, 867 and invoice feeds behind a reserve, and how long each program takes to pay
In shortAn accrual draws on sales from the ERP (enterprise resource planning, the company's core accounting system), wholesaler inventory, resale and claims data, contracts, price files, invoices and last quarter's memo. The numbers 852, 867, 844 and 849 name standard electronic data interchange (EDI) files. These feeds arrive on different days, and most describe a period already past. The payment lag decides how much of a reserve is judgment.
Feed
What it says
What it is used for
What to check
ERP sales
Shipments by product and channel, at list price
The gross line of the bridge
Ties to the general ledger
EDI 852 product activity
Stock on hand and units sold, reported by a trading partner41
Weeks of inventory in the channel; shipments less channel build gives units dispensed
Chargeback credits and the amount still in the channel
Credits tie to the ERP
Prior memos and policy
Methods and the reasons for them
What stays the same, what must change
Assumptions carried forward without a source
Payment lag analysis in the example: from 12 days for copay to 168 for Medicaid
In the example, Medicaid takes 14 times as long to pay as copay
Payment lag by program, in days after the sale, Northwind Bio
Medicaid168 days
Commercial PBM118 days
Medicare Part D74 days
GPO and fees42 days
340B21 days
Other chargebacks18 days
Copay12 days
Fictional example from this guide · The sample company's own analysis of 12 quarters of payments. We found no public table of lags by program. Measure yours.
Show the numbers
Item
Value
Medicaid
168 days
Commercial PBM
118 days
Medicare Part D
74 days
GPO and fees
42 days
340B
21 days
Other chargebacks
18 days
Copay
12 days
Two quarters after a sale, 13% of the example's Medicaid bill is still unpaid
Cumulative share of a quarter's liability paid, by quarter after the sale
MedicaidCommercial PBMMedicare Part D
0%25%50%75%100%100%100%100%
In quarterQ+1Q+2Q+3Later
Fictional example from this guide
Show the numbers
Medicaid
Commercial PBM
Medicare Part D
In quarter
2%
0%
18%
Q+1
56%
71%
82%
Q+2
87%
95%
97%
Q+3
96%
100%
100%
Later
100%
100%
100%
Public filings describe the same gap in words. One maker's report for 2023 said there "continues to be an extensive time lag related to certain programs".23 Another's report for 2025 says there is "frequently a time lag of up to several months" behind its Medicaid rebate notices.45 The statute gives states 60 days after a quarter to report and the maker 30 days after receipt to pay, and interest begins after 37 calendar days from the postmark.5,46
06 · The calculations
Rebate accrual formulas, worked: units, rate, Medicaid share, unit rebate and refund
In shortMost accruals are the same shape: units, times a price, times a rate. What differs is where each factor comes from and how stale it is. Here are five of them, worked with the guide's fictional numbers, and each number is one a reviewer should be able to trace.
Commercial rebate = eligible units × WAC × contract rate
Crestline Rx, exclusive plans, third quarter: 91,000 units × $7,120 × 41% = $265.7 million as scheduled. At the amendment's 44% it is $285.1 million, $19.4 million more. The units are themselves an estimate: resale data and a claims panel, scaled to the PBM's last reported quarter, since the PBM's file is not due until November 14.
Medicaid accrual = dispensed units × Medicaid share × unit rebate amount
Talvoren: 1,120,000 bottles × 36.4% × $986.00 = $402.0 million. The share is the judgment. A four-quarter average of 34.6%, 35.9%, 36.5% and 38.7% gives 36.4%. The latest invoices say 38.7%, and two states made the drug preferred on July 1, which should push it further. At 38.0% the accrual is $419.6 million, $17.7 million more.
Dispensed units = shipments − channel build
Shipments of 1,134,000 bottles, less 14,000 that stayed in wholesaler stock, gives 1,120,000 dispensed. Rebates are owed when the drug is dispensed, so inventory matters: leave it out and the accrual is wrong.
Unit rebate amount = 23.1% of AMP + inflation rebate
For brand drugs the basic rebate is the greater of 23.1% of average manufacturer price (AMP) or AMP less Best Price, plus an additional rebate when price has grown faster than inflation.5,8 Talvoren: AMP of $1,312.40, basic rebate $303.16, additional $682.84, so $986.00 for a drug listed at $1,450.
In the example, 69% of the Medicaid rebate is the inflation rebate
Talvoren unit rebate amount, per bottle
$986per bottle
Inflation-based additional rebate$682.84
Basic rebate, 23.1% of AMP$303.16
Fictional example from this guide
Show the numbers
Part
Value
Inflation-based additional rebate
$682.84
Basic rebate, 23.1% of AMP
$303.16
Negotiated price refund = (WAC − MFP) × units
The federal facilitator's default refund works this way, and the refund advice a maker returns records the method it used.11,33 Dravenzo: list price $612, negotiated price $268, so $344 a unit. A model built on the second quarter's run rate plus 3.5% says 412,000 units and $141.7 million. Claims already received say 445,000 and $153.1 million, $11.4 million more, on nine months of history.
Three decisions, $48.5 million: what the rebuilt numbers change
Three assumptions out of 262 move the example's quarter by $48.5 million
The schedule against the rebuilt figure for the line that changed
ScheduleRebuilt
Crestline exclusive plans, rate$265.7M$285.1M
Talvoren Medicaid, share$402M$419.6M
Dravenzo refunds, units$141.7M$153.1M
Fictional example from this guide · $19.4M + $17.7M + $11.4M = $48.5M, or 1.4% of the quarter's provision. Each is a decision for the controller, and each could also be kept with a reason.
Show the numbers
Schedule
Rebuilt
Crestline exclusive plans, rate
$265.7M
$285.1M
Talvoren Medicaid, share
$402M
$419.6M
Dravenzo refunds, units
$141.7M
$153.1M
07 · Roll-forward and second estimate
The reserve roll-forward, the look-back and a second estimate: three ways to test the number
In shortA reserve should reconcile to itself, agree with the general ledger and survive comparison with what was later paid. Three standard tests do that: the roll-forward, the look-back, and an independent estimate. Each catches a different kind of mistake. The table adds two more: a comparison with the contracts and a sensitivity test.
The example, in millions: $5,210.0 + $3,566.0 + $26.0 − $3,396.0 = $5,406.0. A public example shows the size of the flow. One large maker's most significant US rebate, discount and return liabilities opened 2025 at $10.3 billion, took $62.1 billion from net sales, paid out $57.3 billion and closed at $15.1 billion. It says a 5% change in its consolidated liability would change revenue by about $897 million.47
At one large maker, $62 billion moved through the reserve to leave a $15 billion balance
US sales rebate, discount and return liabilities, 2025
Opening balance$10.3B
Reduction of net sales$62.1B
Cash payments$57.3B
Closing balance$15.1B
Source47 · Form 10-K for 2025. The lines differ from the closing balance by $1 million through rounding.
Show the numbers
Item
Value
Opening balance
$10.3B
Reduction of net sales
$62.1B
Cash payments
$57.3B
Closing balance
$15.1B
Test
How it works
What it catches
What it misses
Roll-forward
Opening, provision, true-up, payments, closing, by program; tie to the general ledger
Missing lines, wrong accounts, stale balances
A wrong rate applied consistently
Look-back, or backtest
Compare an old estimate with what was later paid48
Bias in the method; drifting assumptions
Anything still unpaid; new programs
Independent estimate from payment history
Fit lag curves to past payments and project this quarter
Trends, such as a rising share
A rate that changed in the quarter, with no payments yet
Contract comparison
Every term in force in the quarter against the rate in the schedule
Missed amendments and new plans
Volume and mix
Sensitivity
What one point of Medicaid share, or a week of lag, does to the number
Which assumptions deserve attention
Whether the base is right
Set a review threshold in writing. The example uses $5 million or 2% of the program's provision, whichever is lower, so small programs still get looked at. A threshold lets an auditor test a control, since it says how precise the review is meant to be. Crowe's advice to specialty companies preparing for a launch is the same list: roll forward each category, backtest, document variances and set escalation thresholds.48
08 · Common errors
Ten ways a gross-to-net reserve goes wrong, and which program each one hits
In shortMany reserve errors are ordinary: a term not updated, an average that stopped fitting, inventory left out, a formula that drifted. The public record has cases of the same kind, including one where the information already existed when the estimate was made, which is why contracts, government pricing and accounting have to meet on the numbers.
#
The error
Why it happens
What catches it
1
A signed amendment not in the schedule
Contracting signs in June; accounting rolls last quarter's rate in October
Every term in force compared with the schedule
2
A trailing average past its useful life
The method is written down, and the formulary changed
Trend test plus state notices
3
Channel inventory left out
Accrual did not keep up with growth in wholesaler stock49
852 reconciled to shipments; weeks on hand
4
The wrong list price or price date
A mid-year price change, or a clause tied to list price (price protection) not triggered as assumed
Price file by date; clause test
5
A stale unit rebate amount
Pricing file finalized after the accrual
Government pricing confirms the quarter's amount
6
A retroactive amendment treated as prospective
Effective date earlier than signature; "the new normal"43
Effective dates read from the document
7
A new program modeled on an old one
Nine months of refund claims and no curve
History length stated; actual claims used
8
A category estimated as a blended rate
One percentage for several deductions hides each one48
Missed terms hurt commercial rebates, and stale shares hurt Medicaid
How likely each error is to move each program materially, by our reading
RarePossibleLikely
Missed termStale utilizationInventoryShort historyCommercial PBMLikelyPossiblePossibleRareMedicaidRareLikelyLikelyRareMedicare Part DPossiblePossiblePossibleLikely340B and chargebacksPossibleRareLikelyRareFeesPossibleRarePossibleRareCopayPossiblePossibleRareRare
Our reading of the sources48,43,49 · A judgment for orientation, drawn from the cases and advice cited in this section. We found no public dataset of accrual errors by program.
Show the numbers
Missed term
Stale utilization
Inventory
Short history
Commercial PBM
Likely
Possible
Possible
Rare
Medicaid
Rare
Likely
Likely
Rare
Medicare Part D
Possible
Possible
Possible
Likely
340B and chargebacks
Possible
Rare
Likely
Rare
Fees
Possible
Rare
Possible
Rare
Copay
Possible
Possible
Rare
Rare
Four public cases, from a $290 million rebate adjustment to $20 million of missed information
Public filings show reserves going wrong four different ways over two decades
Mar 2003Rebate liabilities restated
A large maker corrects Medicaid and prime vendor accruals that did not fully reflect growth in wholesaler stock, reversing a one-time charge of about $290 million.
Aug 2004SEC channel stuffing settlement
$100 million penalty and a $50 million fund, without admitting or denying. The SEC alleged wholesaler inventory built up undisclosed.
Mar 2017Rebate obligations miscalculated
A specialty maker restates quarters of 2015 and 2016 over government payer and managed care contracts. The review found no fraud.
Dec 2023Reserves omit available information
A specialty maker's return and price adjustment reserves "did not reflect certain information that should have been considered": $15.0 million to $20.0 million.
We found no public database of reserve errors, so these four illustrate kinds of failure and give no rate. Each company's name appears only in the Sources.
09 · Auditors and errors
Why rebate reserves become critical audit matters, and when a true-up counts as an error
In shortRebate accruals are material and judgmental, so many auditors' reports name them as a critical audit matter. Auditors test the process, build their own expectation or look at what was later paid. The sharpest question is whether a true-up came from new information, which is normal, or from facts you already had, which is an error.
A critical audit matter is one communicated to the audit committee that "relates to accounts or disclosures that are material" and "involved especially challenging, subjective, or complex auditor judgment". The auditor describes it in the published report, for the largest public companies (large accelerated filers) from fiscal years ending on or after June 30, 2019 and for other covered companies from December 15, 2020.52
In searches of fiscal 2025 reports we found a matter on US rebates or gross-to-net accruals at nine drug makers, large and small.3,53,54,55,56,57,58,59,60 This is a sample rather than a full count, and we read these auditors' reports only in excerpts of the filings, as the Sources say.
What auditors do
How it looks in fiscal 2025 reports
What they will ask you for
Test your process: methods, data and significant assumptions25
One report's matter covers Medicaid, Part D and managed care rebate accruals, and that maker's own note lists the judgments behind them: legal interpretations, payer channel mix, unbilled claims, processing lags and channel inventory.3,16 Another points to expected units, actual per-unit rebates and utilization trends.54
Policy, memo, the source of each assumption, controls over each report you rely on
Build an independent expectation, with a reasonable basis for its assumptions25
At one smaller maker the auditor built its own expectation for copay and Medicaid reserves and compared it with the books.55
Raw data the auditor can use: claims, invoices, lags
Look at what happened afterward
One report, at an animal health maker, compares the prior year-end accrual with amounts actually paid.61 Another compares prior-period accruals with later payments.57
Payments and invoices after the balance date, by program
The audit standard adopted in 2018, effective for fiscal years ending on or after December 15, 2020, directs attention to management bias in estimates.25
Why a change this quarter, and why none last quarter
New information or old facts: the question that separates a true-up from a restatement
A change in estimate comes from new information and passes through the current period. An error is a mistake, including an "oversight or misuse of facts that existed at the time the financial statements were prepared". BDO puts it plainly: "if information is misinterpreted or old data is used when more current information is available in developing an estimate, an error exists".22
The size does not decide it either. The SEC staff says relying exclusively on a percentage "has no basis in the accounting literature or the law", and a small misstatement can matter if it "masks a change in earnings or other trends" or hides a miss against analysts' expectations.62
Usually a change in estimate
Second-quarter state invoices arrive in late August and exceed the accrual. Your method was reasonable, and the facts were not yet available. Book it, explain it, and ask whether the method should change.
May be an error; take it to your auditors
An amendment signed before the balance date sat in the contract system while the schedule used the old rate. The fact existed when the statements were prepared. Whether it is material is a further question, and the numbers alone do not settle it.
Changes in estimate at one large maker: small as a share, large in dollars
Prior-period changes were about 1% of one maker's deductions in 2025, and $485 million
Reductions of provisions for earlier periods' sales, as a share of that year's gross-to-net adjustments, our arithmetic
A second large maker says adjustments from changes in estimates on its most significant US liabilities were less than 1%, 3% and 1% of US revenue in 2025, 2024 and 2023.20 SEC rules ask companies to discuss how much a critical estimate has changed over a relevant period and how sensitive the reported amount is, where that is material and reasonably available.63 So a tracked true-up rate serves as a control and as an input to disclosure.
Where the dollars and the judgment meet in the example
Commercial, Medicaid and Part D earn most of the controller's time in the example
Judgment in the estimate →
Small, judgmental
Decide and sign
Check by rule
Large, mechanical
Commercial PBMMedicaidMedicare Part D340BChargebacksFeesCopay
Dollars in the quarter →
Fictional example from this guide · A placement for orientation: dollars from the example's provisions, judgment by our reading of its lags and history.
Show the numbers
Item
Dollars in the quarter (0–1)
Judgment in the estimate (0–1)
Commercial PBM
0.78
0.58
Medicaid
0.58
0.74
Medicare Part D
0.54
0.66
340B
0.34
0.27
Chargebacks
0.24
0.17
Fees
0.16
0.10
Copay
0.10
0.33
10 · The market in numbers
The $416 billion gross-to-net bubble, and what finance teams report about their closes
In shortDrug Channels Institute (DCI) calls the gap between list and net sales the gross-to-net bubble. Its estimate for brand-name drugs reached $416 billion in 2025, though it warns the scope has shifted and the bubble is deflating in parts. Polls and surveys of finance teams show Excel in wide use, Medicaid the hardest to reconcile, and many teams unsure how close their forecasts run to federal invoices. We found no public true-up rate by program.
$416B
of 2025 gross-to-net reductions on brand-name drugs, an estimate. DCI's figure for 2024 was $356 billion, on a wider scope than its estimates through 2023.1,64
Drug Channels Institute, July 2026 and July 2025
51.7%
average discount from list at the three of eight large makers that disclosed one.1
Drug Channels Institute, July 2026
−1.8%
unweighted average net price change at eight large makers in 2025, while list prices rose an unweighted average of 3.7%. The gap between the two is what the reserve has to capture.1
Drug Channels Institute, July 2026
What gross-to-net teams use, and where they struggle to reconcile
Two in three poll responses still name Excel for the gross-to-net process
"What type of system do you use for your GTN process?"
66%Excel
Excel66%
Software product13%
Custom built10%
Outsourced6%
Other5%
Source7 · Audience poll at a 2025 summit, sample size not stated. 23% of the audience were service and solution sellers.
Show the numbers
Part
Value
Excel
66%
Software product
13%
Custom built
10%
Outsourced
6%
Other
5%
Medicaid invoices are the hardest thing to reconcile, by a wide margin
"Where do you struggle most with GTN reconciliation?"
Medicaid invoices71%
ERP integration gaps15%
340B eligibility mapping8%
Chargebacks6%
Source7 · Audience poll at a 2025 summit, sample size not stated.
Show the numbers
Item
Value
Medicaid invoices
71%
ERP integration gaps
15%
340B eligibility mapping
8%
Chargebacks
6%
Nearly 4 in 10 poll responses are not sure how close their Part D redesign forecast runs to CMS invoices
39 in 100
poll responses said "not sure". 23 said within ±5%, 18 within ±10%, 10 within ±20%, and 10 said further off than that. Audience poll, sample size not stated.
poll responses said "not sure". 23 said within ±5%, 18 within ±10%, 10 within ±20%, and 10 said further off than that. Audience poll, sample size not stated.
39 of 100
Surveys by software sellers point the same way, and should be read as sellers' research. In one revenue software seller's 2026 report, 429 director-level and higher US leaders in pharma and medtech took part, 99% said managing gross-to-net has become more challenging, and 94% were confident their government pricing reports could withstand an audit.65 Its pharma summary says 96% believe better processes would materially affect margins, and it names PBM demands (67%), government programs (60%) and patient assistance and payer countermeasures (59%) as the causes.66
Two forces pull the other way. DCI says the bubble "is growing more slowly—and even deflating in parts of the market", and lower list prices can reduce rebate obligations and even raise net prices, as one maker's insulin cut did.1 The large maker in section 02 shows it: its share fell to about 30% of gross in the third quarter of 2026, from about 47% a year earlier, after a US list price cut.17 If list prices fall, expect some of these reserves to shrink, along with the patterns your lag curves were fitted to.
What nobody publishes. We found no public figure for accrual error rates, true-up rates by program, hours or cost per close, or staff per billion of gross sales. Trace any you see quoted back to its source. Part C shows how to measure your own.
11 · What software can do
Automating gross-to-net accruals: what AI can read and compare, and what stays a judgment
In shortReading contracts, tying feeds, rebuilding formulas and drafting memos are good jobs for software, including AI. Choosing an assumption, deciding what a clause means and signing the number stay with a person. No regulator has written a rule for AI in rebate accruals, so the test is internal control and evidence an auditor accepts.
Job
What software adds
The limit
Read contracts and amendments
Every rate, tier, fee and date, linked to its clause, re-read when a new amendment appears
A reading can be wrong. Plant errors and count. Interpretation stays with contracting and counsel
Tie the feeds
Completeness checks on every file, each run
A complete file can still be a wrong one
Rebuild the schedule
Formulas regenerated from source, so a tab cannot drift
Only the methods you approve
Second estimate
Lag curves refreshed each quarter, with the history length stated
Blind to changes with no payments yet
Explain variances
A cited first draft of the cause, with options and dollar effects
Which option is right is a judgment
Draft the memo and answer auditors
Only what changed, every number linked; evidence matched to each request
A person reads it, signs it and sends it
Adoption is early by one measure and universal by another. In the summit's audience poll, which states no sample size, 51% said they are "just starting to introduce" AI automation in data management and 29% do not use it or do not know.7 One software seller's survey says 97% use AI solutions for revenue management.66 These are different questions put to different people, so neither settles it.
Half of poll responses are just starting with AI, and one in five call it pervasive
"To what extent is your organization incorporating AI automation within your data management approach?"
Very pervasiveSomewhat pervasiveJust startingDo not use it or don't know
All responses14%51%29%
Source7 · Very pervasive is 6%. Audience poll at a 2025 summit, sample size not stated.
Show the numbers
Very pervasive
Somewhat pervasive
Just starting
Do not use it or don't know
All responses
6%
14%
51%
29%
The biggest challenge to analytics in the summit poll was "developing accurate assumptions", at 51%, ahead of clean data at 32%.7 Reading documents faster does not choose the assumption for you.
Accurate assumptions outrank clean data as the biggest challenge to gross-to-net analytics
"What is your biggest challenge to effective GTN analytics?"
Developing accurate assumptions51%
Clean, detailed data and actuals32%
A reliable, flexible modeling tool11%
Well-defined roles6%
Source7 · Audience poll at a 2025 summit, sample size not stated.
Show the numbers
Item
Value
Developing accurate assumptions
51%
Clean, detailed data and actuals
32%
A reliable, flexible modeling tool
11%
Well-defined roles
6%
How internal control applies when AI touches a reserve
FDA's January 2025 draft guidance on AI covers information that supports regulatory decisions on drugs, which leaves reserves outside it.67 The frame here is financial reporting. Management assesses internal control each year under Sarbanes-Oxley section 404.40 The Committee of Sponsoring Organizations (COSO) published Achieving Effective Internal Control Over Generative AI in February 2026, with control considerations by type of use, among them human and AI interaction, and metrics that can support audit evidence.68 Coordinate with your auditors on what they will accept before the first close.
A control question
What good looks like
Is the output a control or an input?
An AI reading is an input; a named person's review with a stated threshold is the control
Can the reviewer see what it rests on?
Each number opens the clause, file row or curve behind it
What if the model or prompt changes?
Version recorded; re-test on planted errors before the close
Who can change a signed number?
Nobody in place; a new version with a reason, both kept
Is report data complete and accurate?
Tie-outs run each time, with results kept for the auditor
12 · How the close runs today
How gross-to-net teams close today: five roles, six steps and spreadsheets throughout
In shortAn accounting team pulls feeds and rebuilds each program's schedule. A controller reviews and signs, government pricing supplies the Medicaid inputs, and a liaison answers auditors. In the example the close takes nine working days and 670 hours, most of it compiling. Teams run it in spreadsheets, in a revenue management system, or with outside help.
The five roles a quarter's reserves pass through
GA
Gross-to-net accounting manager
Builds the schedules from ERP, channel data, invoices and contracts; keeps the roll-forward; prepares the memo.
Cares about: getting everything tied by the deadline.
RC
Revenue controller
Owns the policy, reviews variances above the threshold, decides the judgments and signs.
Cares about: what each number rests on.
GP
Government pricing lead
Owns average manufacturer price, Best Price and unit rebate amounts, and the certified reports behind them.44
Cares about: one right amount per drug and quarter.
AL
External audit liaison
Answers the auditor's request list, often called the PBC list ("provided by client").
Cares about: evidence that is complete the first time.
NP
FP&A net price lead
Reads reserves and true-ups for the forecast; feeds channel and mix views back.
Cares about: why net price moved.
Finance owns the process in 73% of the summit's poll responses, and 25% say a mix of functions; the report states no sample size.7 KPMG lists the teams a cycle crosses: contracts, pricing, government pricing, revenue accounting, FP&A, legal and accounts payable, and describes them as teams that do not communicate well with each other.6
From quarter end to signed reserves: who holds the work on which day
A reserve passes through five teams inside the close calendar
1Feeds in
ERP, 852 and 867, invoices, claims; tie to the general ledger.
GTN accountingDays 1–2
2Contracts read
New agreements and amendments, effective dates.
Contracting, then GTN accountingDays 2–3
3Schedules rebuilt
Seven programs, roll-forward, unit rebate amounts.
GTN accounting and government pricingDays 3–6
4Variances explained and decided
Against a threshold and last quarter.
Revenue controllerDays 6–8
5Memo written
Methods, assumptions, changes.
GTN accountingDays 8–9
6Auditor requests answered
Evidence and completeness checks.
Audit liaisonDays 9 and after
Fictional example from this guide · A typical sequence set to the example's nine working days. We found no published standard calendar.
Show the numbers
Step
What happens
Who
Time
Feeds in
ERP, 852 and 867, invoices, claims; tie to the general ledger.
GTN accounting
Days 1–2
Contracts read
New agreements and amendments, effective dates.
Contracting, then GTN accounting
Days 2–3
Schedules rebuilt
Seven programs, roll-forward, unit rebate amounts.
GTN accounting and government pricing
Days 3–6
Variances explained and decided
Against a threshold and last quarter.
Revenue controller
Days 6–8
Memo written
Methods, assumptions, changes.
GTN accounting
Days 8–9
Auditor requests answered
Evidence and completeness checks.
Audit liaison
Days 9 and after
Where nine working days and 670 hours go in the example
Rebuilding schedules and reading feeds and contracts take most of the example's close
Working days by task, one quarter by hand
FeedsContractsSchedules and roll-forwardVariances and reviewMemo and auditor requests
By hand, 9 days1.51.52.51.52
Fictional example from this guide · The sample company's own estimate. Effort in the same example: 410 hours compiling, 140 reviewing, 120 answering auditors. We found no public study of these. Time your own.
Show the numbers
Feeds
Contracts
Schedules and roll-forward
Variances and review
Memo and auditor requests
By hand, 9 days
1.5
1.5
2.5
1.5
2
In-house macros, a revenue system or a provider: three ways to run the close
In house
Spreadsheets and macros
Most common by the poll.7 Quick to change when a program arrives. The weak points are links, versions, one person's knowledge and support that gets rebuilt for each audit.
Software
Revenue management or gross-to-net modules
37% of poll responses have a revenue management system; 13% name a gross-to-net software product.7 Strong on contracts, claims and calculations, and teams still tend to keep the accrual judgment and memo outside it.
Outsourced
A provider runs the data or the model
6% of poll responses outsource the process, and 74% rely on third parties for at least half of data management.7 The hours move, and you still own the estimate and the control.
Part B · See it working
Closing a $3.57 billion quarter of reserves in Botminds Gross-to-Net Accruals
Part A described the work without naming a product. This part shows how Botminds does it, at a fictional drug maker, Northwind Bio, closing the third quarter of 2026. Every company, person, drug, contract clause and number in the screens is sample data, and the clauses and policy text are sample text written for the example.
13 · One decision, start to finish
One $19.4 million amendment at Northwind Bio, from flagged rate to the auditor's answer
In shortThis is the example from the top of the page, inside the product. The home screen is the gross-to-net bridge. Lena Ortiz, the revenue controller, opens the commercial step, sees the rate that disagrees with its source, takes the contract rate, signs, and the auditor's request fills in. A person decides each number; agents do the reading and rebuilding.
1
Gross sales to net revenue on one screen
It is Wednesday, October 7, 2026, working day 5 of 7. Reserves lock Thursday at 5:00 pm. Lena's home screen opens on the bridge: $6.84 billion of gross sales stepping down through seven programs to $3.27 billion of net revenue.
Each step is marked. Commercial PBM, Medicaid and Medicare Part D carry "Your decision", with their variances: +$19.4 million, +$17.7 million and +$11.4 million. 340B and chargebacks are ready to sign. GPO fees and copay were signed on October 6. Across the top: 257 of 262 assumptions tied to a source.
The gross-to-net bridge. Each step is one reserve program, with its stage, variance and cause printed under it.
2
The step opens to its formula and its clause
Lena clicks Commercial PBM, and the build opens under the bridge. For Crestline Rx's exclusive plans: 91,000 units × $7,120 × 41.0% = $265.7 million. The rate box is flagged. "Source says 44.0%."
Beside it, 64 of the program's 66 assumptions, each with its document. Beside that, the passage: Amendment No. 3, section 4.2, sample text, effective July 1, 2026. Two assumptions were carried from the prior memo, and they are marked for Omar Haddad to support.
The commercial step, open. The formula with its flagged factor, every assumption with its source, and the sample clause highlighted.
3
She takes the contract rate, and net revenue moves
The finding says what to do and why: the amendment was signed June 24 and covers every third-quarter unit on the 38 exclusive plans. Lena picks "Use the contract rate". She could also keep the schedule's rate, with a written reason.
The step grows to $1,439.4 million, and net revenue falls to $3.25 billion. The reserve at September 30 becomes $2,646.4 million for the program. The roll-forward moves with it.
Decision recorded. The step, the accrual and net revenue update at once, ready for her signature.
4
A signature with its meaning, and the program locks
The signing screen sums it up: provision, reserve, independent estimate, decision, evidence. She signs "I reviewed this reserve and its evidence and approve it".
The program locks. A later change needs a new version with a reason, and both stay in the audit trail.
Signing a program. What she is signing, the meaning of the signature, and what signing does.
5
The auditor's request comes with its evidence
Hartwell & Lane LLP, the sample audit firm, sent 12 requests, due October 14. PBC-03 asks for commercial rebate agreements and amendments effective in the quarter. The listing has been checked as complete against the contract system, 20 of 20, and Amendment No. 3 is attached.
With the program signed, a response is drafted: six amendments were effective, one changed a rate used in the reserve. Priya Ranvelle, the audit liaison, reads it and sends it. The auditor opens the same passage Lena saw.
The audit pack. Twelve requests with status, the evidence, completeness checks, the drafted response and the passage the auditor will open.
On these screens the independent estimate for commercial PBM equals the rebuilt figure to the dollar. Read that as the sample's arithmetic: as section 07 explains, a payment-based estimate cannot see a rate that changed in the quarter being closed, and in practice the contract comparison finds it.
14 · Every screen
Medicaid share, Medicare refunds, the reserve memo and the settings around the close
In shortOne amendment is the story. These screens show the rest of the close: the programs against their estimates, the two other decisions, the sources behind them, lags and true-ups, the memo that rewrites only what changed, the dashboard, and the settings that belong to you.
Seven reserve programs against an independent estimate
Reserve programs. Provision, independent estimate, variance against the threshold, payment lag, sourced assumptions and stage.
The roll-forward. June 30 to September 30 by program, $5,210.0 million to $5,406.0 million before her decisions, beside the auditor's open requests.
The Medicaid decision: a trailing average against two formulary changes
The schedule uses a four-quarter average of 36.4%. The second-quarter state invoices came in at 38.7% and produced a $36.0 million true-up, and two states made Talvoren preferred on July 1. Lena sees three options with their effect: 38.0% (+$17.7 million), 37.5% weighted over three quarters (+$12.1 million) or 36.4% kept with a reason. The prior memo allows a departure for a known formulary change, and the screen cites that sentence. Dana Okafor, the government pricing lead, owns the unit rebate amount, which matches the third-quarter pricing file.
The Medicaid finding. The schedule's share, the recommended share and the three options, with the source beside them.
The unit rebate, sourced. Average manufacturer price, basic rebate and inflation rebate, in the sample pricing file.
Dispensed units, sourced. Shipments less channel build, from the wholesalers' 852 data.
Lag and roll-forward. The share of a quarter paid by each later quarter, and this program's balance.
True-up history. Five quarters of Medicaid under-accruing, which is what a look-back is for.
Medicare refunds on nine months of history
Dravenzo's negotiated price refund claims total 445,000 units for the quarter against a model of 412,000, at $344 a unit (list price of $612 less the $268 negotiated price). The Lag Curve Analyst flags the nine months of history, and the sample's policy says that with under 12 months it books the higher end of its range. Using the actual claims adds $11.4 million. Part A sets out the real test: ASC 606 asks whether a significant reversal is probable, and your policy says how you apply it.
Medicare Part D. Refund claims against the model, the short history flagged, and how the agents built the number, step by step.
Any source, opened at the passage. Read-only and versioned, with where else it is used. Sample contract text.
A reserve memo that rewrites only what changed
Her decision makes the memo draft stale, and the screen says so. The Memo Writer redrafts only the affected sentences: section 4.1 now records the amendment, the 41% the schedule had used and the $19.4 million increase, decided by the Revenue Controller on October 7. Medicaid and Part D show as waiting. Nothing is guessed. All 41 numbers link to a source passage and are re-checked before signing, and the memo cannot be signed while a program is unsigned.
The memo, stale. A banner when decisions have moved since the draft, with the policy passage behind a citation.
The memo, redrafted. Section 4.1 from the signed decision, with pending decisions shown as waiting.
The reserve dashboard: true-ups, lags and where gross-to-net goes
Sam Patel in FP&A reads the dashboard. On the sample, true-ups fell from 1.7% of provision to 0.73% over six quarters, against a target under 0.5%. These are sample figures that show how the screen works, and they prove nothing about a real company. True-ups by program show Medicaid's +5.3% this quarter as the place the earlier estimate was furthest off.
The dashboard. Gross-to-net share, reserve, true-up rate, days to sign, sourced share, the trend and the mix.
Lags and true-ups. Payment curves by program, true-ups by program and quarter, and close effort at the design target.
Your reserve policy as settings: threshold, approvers, methods and rules
The threshold, approvers, estimation methods and rules are settings, and every change is on the audit trail. One rule cannot be switched off: any variance above the threshold routes to the Revenue Controller.
Threshold and approvers. $5 million or 2%, whichever is lower, and who signs what.
Methods and rules. Medicaid utilization method, lag history, the short-history constraint and the checks that always run.
About 340B on these screens: the sample's 340B line includes rebate claims on Dravenzo alongside ceiling-price chargebacks. That is sample data. The real rebate pilot is described with its dates in section 04, and it has not started.
15 · Agents, and who signs
The revenue controller signs every reserve; six agents do the reading, rebuilding and drafting
In shortEach agent has one job and limits it does not cross. None of them signs, sends to the auditor or decides a judgment. Variances above the threshold always go to the Revenue Controller, government pricing signs unit rebate amounts, and the audit liaison sends each response.
Contract Terms Reader to Audit Pack Assembler: each agent's job and its limit
Contract Terms Reader
Reads rebate agreements and amendments, extracts rates, tiers, plans, fees, price protection and effective dates with their clause, and compares each term in force with the rate in the schedule.
Never infers a rate that is not written. Unsigned drafts are flagged separately.
Lag Curve Analyst
Fits payment lag curves from 12 quarters of paid invoices and produces an independent run-rate estimate for each program.
Never hides the history. It states the length used, and flags anything under 12 months.
Reserve Builder
Rebuilds each accrual from source: units, shares, rates and channel inventory. Carries a citation on every assumption and keeps the roll-forward, tied to the general ledger.
Never overwrites a signed schedule. It creates a new version.
Variance Checker
Compares each schedule with the independent estimate, writes the cause with citations, proposes options with their dollar effect and routes what is above the threshold.
Never decides a judgment. It proposes.
Memo Writer
Drafts the reserve memo from the template out of signed schedules and decisions, rewrites only what changed, and re-checks every number against its source.
Never guesses a pending decision. It shows it as waiting, and leaves no number uncited.
Audit Pack Assembler
Matches each auditor request to its evidence, runs completeness and accuracy checks on each report used, and drafts a short response.
Never sends. Only signed programs go out, and the liaison sends each response.
Where people decide: the controller's variances, pricing's unit rebates, the liaison's responses
Decides and signsRevenue controllerEvery variance above the threshold, each program and the memo. Keeping the schedule needs a reason.
PreparesGross-to-net accounting managerReviews what was rebuilt and supports assumptions carried from the prior memo.
Signs the unit rebateGovernment pricing leadOwns average manufacturer price and unit rebate amounts.
SendsExternal audit liaisonReads and sends each response. Nothing leaves without a person.
ReadsFP&A net price leadReserves, true-ups and mix for the forecast.
Maker-checker is built in: one person prepares, another approves. These roles are the sample's settings, and yours to change. The agents and signatures support your internal control over financial reporting, and your management and auditors still assess it.40
What each person on the sample close wants from the reserves
Fictional, from the sample data
LO
Lena Ortiz · revenue controller
Owns policy RA-12, decides and signs.
"Show me what the number rests on, and I can sign it today."
OH
Omar Haddad · gross-to-net accounting manager
Prepares the seven schedules.
"I spend the close compiling support instead of checking judgment."
PR
Priya Ranvelle · external audit liaison
Answers the audit firm's 12 requests.
"Every request is the same question: where did this come from?"
DO
Dana Okafor · government pricing lead
Owns average manufacturer price and unit rebate amounts.
"If the unit rebate is wrong, every Medicaid number is wrong."
SP
Sam Patel · FP&A net price lead
Reads reserves and true-ups for the forecast.
"Tell me which program moved net price, and why."
16 · What goes in and out
From contracts, 852 data and state invoices to a signed bridge, a cited memo and an audit pack
In shortThe solution reads the feeds a close already runs on and leaves behind a signed bridge, schedules and roll-forward, a memo with a citation on every number, and answers to the auditor. Your ERP and contract system stay the systems of record. Targets below are design targets, measured in the live solution on your own data.
Sales and channel feeds
ERP sales by product and channel
852 wholesaler inventory
867 resales and the claims panel
844 and 849 chargeback lines
Contracts, invoices and policy
Rebate agreements and amendments
State Medicaid invoices and formulary notices
PBM utilization and Medicare refund claims
Prior reserve memos and your accounting policy
Agents read, rebuild and checkEvery program, every assumption, against its source and a second estimate
The revenue controller decides
Every number beside its source
Outputs
Signed gross-to-net bridge from gross sales to net revenue
Program-by-program schedules and roll-forward
Reserve memo with a citation on every number
Responses to the auditor's request list
True-up and lag views by program
What changes for the team
Decisions arrive written up, with options
Support exists before anyone asks
A record behind every signature
Nine working days to six at the design target, task by task
The design target takes signed reserves from working day 9 to working day 6
Working days by task in one quarter's close, by hand and at the solution's target
By hand (estimate)With the solution (design target)
Pulling and checking feeds1.5 days1 day
Reading contracts and amendments1.5 days0.5 days
Rebuilding schedules and roll-forward2.5 days1.5 days
Explaining variances and review1.5 days1.5 days
Drafting the memo1 day0.75 days
Answering the auditor's list1 day0.75 days
Illustrative · replace with your own numbers · The solution's own estimate and target for a sample company, untested on yours. Review time stays the same by design.
Show the numbers
By hand (estimate)
With the solution (design target)
Pulling and checking feeds
1.5 days
1 day
Reading contracts and amendments
1.5 days
0.5 days
Rebuilding schedules and roll-forward
2.5 days
1.5 days
Explaining variances and review
1.5 days
1.5 days
Drafting the memo
1 day
0.75 days
Answering the auditor's list
1 day
0.75 days
6 days
Working days to signed reserves, three sooner than working day 9.
Design target
355 hours
Of close effort saved each quarter, 670 to 315, because the evidence is compiled as the work runs.
Design target
98%
Of reserve assumptions tied to their source, 257 of 262 on the sample quarter.
Design target
The eight systems a gross-to-net close draws on
ERPSales, general ledger, payments
Contract repositoryAgreements and amendments
Revenue management or rebate systemInvoices, claims, calculations
Government pricing systemAMP, Best Price, unit rebate amounts
Channel data hub852 and 867 feeds
Chargeback system844 and 849 lines
Medicare facilitator filesRefund notices and advices
Identity and accessRoles, approvers, separation of duties
For each, check whether it has an API, a file feed, or only screens, and who owns it. The screens read these sources and never overwrite them.
What does not move: policy, ERP, signatures and the audit relationship
Your accounting policy
Threshold, methods and rules are yours and are settings. A change is recorded with who and when.
Your systems of record
ERP, contract system and rebate engine stay in place. Sources are read-only and versioned.
Your schedules' logic
The method per program comes from your memo. The rebuild follows it, and any change to it goes through your controller.
Your signatures
Each program is signed with its meaning. A signed program is read-only; a later change needs a new version, and both are kept.
Your audit relationship
The liaison sends. Only signed programs go out, and the auditor opens the same passage the controller saw.
Your scale
Built for enterprise closes: multiple products and programs, role-based access, maker-checker, an audit trail on every decision, rebuild, redraft and send, and data in your own environment. SOC 2 Type II audited, and information security managed to ISO 27001.
Part C · Are you ready to automate?
Deciding whether to automate reserves: the price of a wrong estimate, the return and a closed-quarter test
You build these reserves, or sign them, or answer for them to an audit committee. This part is written for you: what a wrong or late estimate costs, what automating the work could return, whether your team is ready, and what to ask any vendor of gross-to-net software, including us.
17 · What a wrong estimate costs
The price of a missed rebate term: restatements, surprise true-ups and audit hours
In shortA wrong accrual seldom changes the cash you owe. It changes which quarter shows the cost, and whether your numbers can be trusted. The cost shows up as true-ups that move results, audit findings, disclosures and close hours. Start from your own true-ups: we found no public rate.
$485M
of reductions to earlier periods' provisions at one large maker in 2025, against $159 million in 2024. About 1.2% of its deductions, and still a large number.16,2
Form 10-K for 2025 · one maker
$897M
the revenue change another large maker reports for a 5% change in its sales return, rebate and discount liability.47
Form 10-K for 2025 · one maker
$150M
paid in a 2004 SEC settlement, without admitting or denying, over alleged channel stuffing, inventory build-up and reserves.24
SEC Litigation Release 18822
At $500 million of provision a quarter, each tenth of a point of true-up moves $500,000
Size of the true-up in one quarter at a given share of provision
0.5% of provision$2.5M
1% of provision$5M
1.4% of provision$7M
3% of provision$15M
Illustrative · replace with your own numbers · $500 million is an assumption; use your own provision. We found no public benchmark for a true-up share. 0.5% and 1.4% come from the solution's sample target and sample history.
Show the numbers
True-up share
Dollars a quarter
0.5% of provision
$2.5M
1% of provision
$5M
1.4% of provision
$7M
3% of provision
$15M
Eight quarters of true-ups: finding your own number in a week
Cost
Where it hides
How to find your number in a week
True-ups by program
Inside revenue, explained in a sentence
From the roll-forward: eight quarters of prior-period adjustments as a share of provision, by program
Facts you already had
True-ups called a change in estimate
Take the three largest. When did the fact behind each become known inside the company?
Amendments reaching the schedule late
Between contracting and accounting
Days from signature to first use in a schedule, for last year's amendments
Close hours
Salaries, overtime, contractors
Timesheet one close: compiling, reviewing, answering auditors
Auditor requests
Staff time, audit fee discussions
Requests per close, and how many took a second round
Unsourced assumptions
Prior memos and individual people
Pick 30 assumptions in the latest schedule; how many can you source in a minute?
Material weaknesses, earnings surprises and the person who left
A material weaknessManagement assesses internal control each year, and a reserve failure can land there.40 Three of the public cases in section 08 reached filings that restated results or said earlier statements could no longer be relied on.49,50,51
A miss against expectationsThe SEC staff says a small misstatement can matter if it masks a trend or hides a miss against analysts' expectations.62
Price reportsRebates in the Best Price base feed Medicaid.69 Knowingly false price information carries up to $236,451 per item, and late data $23,647 a day.5,70
The person who leftWhen the logic lives in one person's spreadsheet, a resignation is a control issue.
Your controller's weekHours spent finding support instead of testing judgment.
18 · Your return
What automating gross-to-net accruals returns: close hours saved and true-up dollars narrowed
In shortPut in your own numbers. The calculator keeps two things apart: hours, which are money only if you redeploy them, and true-ups, which mostly move results between quarters. On hours alone this work may not pay. The case rests on what you decide a smaller surprise and a cleaner audit are worth.
The six gains from automating a reserve, each with its formula
Missed terms
Every amendment compared
A rate change reaches the schedule in the quarter it takes effect.
units × list price × rate difference
Stale trends
Assumptions tested each close
A second estimate and state notices challenge a trailing average.
units × share difference × unit rebate
True-ups
Narrower surprises
Smaller prior-period adjustments in reported revenue.
provision × (true-up today − target)
Close hours
Compiling cut
Feeds tied and schedules rebuilt before anyone opens them.
hours saved × 4 × hourly cost
Audit
Evidence ready when asked
Fewer second rounds on requests, and less rebuilding of support.
rework hours avoided × hourly cost
Timing
Signed earlier
Days back for review, or for an earlier close.
working days earlier, before and after
Your provision, true-up share, close hours and cost
Starting and target values come from the solution's sample and design target, and describe no real company. Every input marked illustrative is an assumption.
Your reservesHours and cost
Illustrative yearly view
Close hours freed0
Hours freed and rework avoided, valued$0
Time value after your yearly cost$0
True-up a quarter today$0
True-up dollars narrowed$0
Remaining cost per dollar of true-up narrowed0%
Formulas, per year: Hours freed = 4 × (hours today − hours after) Time value = (hours freed + rework avoided) × hourly cost After cost = time value − yearly cost True-up today = provision × true-up today Narrowed = 4 × provision × (true-up today − true-up after) Remaining cost per dollar = (yearly cost − time value) ÷ narrowed
Narrowed true-ups are no cash saving: what you owe stays what you owe, and they mostly move revenue between quarters. Released hours are value only when you decide what they are for. Not counted: audit findings, restatements, price report errors.
On the defaults, a $500 million quarterly provision narrows $18 million of true-ups a year
True-up dollars narrowed a year on the calculator's defaults (1.4% to 0.5%), at three provision sizes
$200 million a quarter$7.2M
$500 million a quarter$18M
$1 billion a quarter$36M
Illustrative · replace with your own numbers
Show the numbers
Provision
Narrowed a year
$200 million a quarter
$7.2M
$500 million a quarter
$18M
$1 billion a quarter
$36M
On the defaults, time value does not cover the yearly cost, and the remainder is about 1.1 cents per dollar of true-up narrowed. Whether that is worth paying is your audit committee's kind of question. A team with few programs and small true-ups should see that clearly and may wish to stay where it is. A team with fresh Medicare programs, a large Medicaid book and auditor pressure has more reason to test it.
Start here19 · Readiness check
Eight questions on whether your reserve process can take automation: contracts, feeds, methods, true-ups
In shortPick the answer closest to your team today. Eight questions score 0 to 2, and the last one is for reflection. The meter adds up your score as you go, and each question says why it matters and what a strong answer sounds like.
1
Programs and dollars
How many programs do you reserve for, and how much a quarter?
Why it mattersVolume and program count turn small percentages into a business case. A company with two programs and little Medicaid may not need this.
A strong answer"Seven programs, three products, over $500 million of provision a quarter."
2
Contracts in one place
Can you list every agreement and amendment effective in a given quarter, today?
Why it mattersA missed amendment starts here. Your auditors will ask for the listing and test its completeness.
A strong answer"Contract operations keeps one repository, and each amendment has an effective date we can report on."
3
Feeds
Do your channel, invoice and claims feeds arrive in a form software can read and tie out?
Why it mattersReport data has to be complete and accurate. Software can check every run, if it can reach the data.
A strong answer"852 and 867 feeds are daily and reconciled to the ERP, and state invoices load into one table."
4
Methods written down
Is the method for each deduction written, including when to depart from it?
Why it mattersSoftware can follow a method only if one exists. Advisers warn against a single blended percentage across deductions.48
A strong answer"A memo per program, with stated triggers for departing from the trailing average."
5
Your true-up baseline
Do you know your true-up rate by program, and how many came from facts you already had?
Why it mattersWe found no public benchmark, so your own baseline is the only way to prove an improvement.
A strong answer"Eight quarters by program. Two of the last ten were amendments we had on file."
6
A review threshold
Do you have a written precision for the controller's review, and evidence that it operates?
Why it mattersA threshold makes a review testable. Your auditors will look for it.
A strong answer"$5 million or 2% of the program, whichever is lower, with decisions recorded."
7
Owner and budget
Is there a named owner of the gross-to-net process with a budget to change it?
Why it mattersThis work crosses finance, contracting, government pricing, trade and IT. In a 2025 summit poll with no stated sample size, 73% of responses said finance owns it and 25% a mix.7
A strong answer"The corporate controller sponsors it, and the CFO has seen the true-up analysis."
8
Auditors and AI
Have you discussed with your auditors and IT how AI output would fit into your controls?
Why it mattersManagement answers for internal control, and COSO published AI control guidance in February 2026.40,68 It is cheaper to agree on evidence first.
A strong answer"Our auditors have seen the design, and every number has a named reviewer and a recorded test."
9
What a number rests on · for reflection
If your auditor picked one assumption from last quarter's Medicaid schedule tomorrow, what would have to be true for you to show its source in under a minute?
Why it mattersYour answer lists the gaps. Each gap is a candidate job for software: reading, tying out, rebuilding or writing up.
A strong answerA short, specific list, for example: "each assumption linked to its file, the share trend by quarter, the state notices, and the reason for the method."
From 0 to 16: measure true-ups, pilot on a closed quarter or plan every program
0–6
Explore
Build the baseline: eight quarters of true-ups by program, contracts in one place, a method per deduction, an owner. Start with the program that gave you the largest surprise.
7–11
Ready to pilot
Re-run one closed quarter on your own contracts and feeds, with errors planted in copies. Compare catches, false flags and hours with your current process, and keep your people deciding every number.
12–16
Ready to implement
Plan every program: methods and thresholds as settings, approvers, ERP and contract links, government pricing sign-off, and what your auditors will test.
20 · Questions for any vendor
Fifteen questions that test a gross-to-net vendor on amendments, lag curves, memos and audit evidence
In shortAsk every vendor the same questions, us included. The answers show how the estimates are built: what the tool reads, how it finds changes, what the second estimate can and cannot see, what your auditors will get, and how you would measure it on your own close.
Ask
A good answer
A warning sign
Contracts and terms
How does a signed amendment reach the schedule, and how fast?
Compared with the schedule each close, by effective date, and flagged with the clause
"Your team keys it in"
Can I open the clause from any rate in the schedule?
Yes, at the passage, read-only
A table of terms with no link
What about retroactive amendments and unsigned drafts?
Retroactive effects shown by period; drafts flagged and left out
The latest version simply overwrites the last
Estimates
What is your independent estimate built from, and what can it not see?
States its inputs and blind spots; a payment-based curve misses a change with no payments yet
"Our model finds everything"
How do you handle a program with under a year of history?
States the length, and routes it under your policy
A curve fitted to a few points, unflagged
How do you treat channel inventory?
From 852 data, reconciled to the ERP, with a stated flag level
Shipments treated as dispensed
Can I use more than one Medicaid share method, and see each effect?
Methods are settings; options show the dollar effect
A single fixed average
People and signatures
Who decides a variance, and what is recorded?
A named person, with reason and time; the tool proposes
Automatic posting to the schedule
What happens to a signed number when something changes?
It stays locked; a new version with a reason, both kept
Numbers change silently after sign-off
Audit evidence
How is report data shown to be complete and accurate?
Tie-outs run each time, kept with the request
A statement on a slide
Can an auditor follow a memo number back to its source?
Every number linked, opening the same passage the controller saw
A PDF and a data dump
Has any auditor reviewed this design?
Says who could speak to it, and what they looked at; no certification claimed
"Audit-approved" with no detail
Your data and AI
Which AI models do you use, where do they run, and does our data train them?
Named models, a region you choose, no training on your data, in writing
"Proprietary AI", no more detail
What accuracy have you measured on contract reading, by term type?
Numbers with their test set, and an offer to measure on yours
"99% accurate" with no method
What happens when a model changes?
Versioned, re-tested, recorded, with notice
Changes you learn about at audit
21 · How to start
Test gross-to-net automation on a closed quarter, then run one close in parallel
In shortMeasure first. Then re-run a closed quarter with errors you planted, because you already know the answers. Then run one live close in parallel with your normal process. Decide on three numbers. None of these steps commits you to a vendor.
Measure your baseline: eight quarters of true-ups by program, and hours in one close.
Ask your auditors early what evidence they would want if software reads contracts and drafts the memo.
Copy one closed quarter: contracts, feeds and schedules. Plant known errors, such as a missed amendment, a stale share and inventory left out.
Run one close in parallel, with your people deciding and your normal process still booking the numbers.
Decide with three numbers: catch rate by error type, false flags on clean items, and hours to signed reserves.
A 20-week test covers one closed quarter and one live close
Your teamVendor
Measure true-ups and hours; talk to auditors
Choose programs; copy a closed quarter; plant errors
Connect feeds and contracts; set methods
Re-run the closed quarter and score it
Parallel run on one live close
Decide on three numbers
Week 05101520
Illustrative · replace with your own numbers · Timing depends on your close calendar: set the parallel run around a real quarter end.
Show the numbers
Activity
From
To
Measure true-ups and hours; talk to auditors
0
3
Choose programs; copy a closed quarter; plant errors
2
5
Connect feeds and contracts; set methods
3
9
Re-run the closed quarter and score it
8
11
Parallel run on one live close
11
18
Decide on three numbers
18
20
Three deciding numbers, plus reading accuracy and a back-test
Measure
How
Why
Catch rate by error type
Planted errors caught ÷ planted, per type, with the number planted
One percentage hides the missed amendments
False flags
Variances raised on clean items, in reviewer minutes
Each false flag costs a controller's time at the worst moment
Term-reading accuracy
300 random terms checked by hand against their clauses
If none of 300 is wrong, the true error rate is very likely under 1%
Hours to signed reserves
Compiling, reviewing and answering auditors, timed for both runs
Compiling should fall; review should not
Back-test
The re-run estimate against what was later paid, by program
Shows whether the second estimate adds anything
The full working-session questions: 12 questions in four groups
Bring accounting, contracting, government pricing, trade, IT and internal audit into one room. Each question says why it matters, what a strong answer looks like, and the warning sign.
A
Programs, products and the reserve policy
A1
Which programs carry most of the dollars and most of the judgment?
Why it mattersSets the first program.
Strong answer · warning sign
A ranked list by both.
"All of them equally."
A2
Which programs have under 12 months of history, and what does the policy say?
Why it mattersNew programs are the hardest to support.
Strong answer · warning sign
Named, with a written approach.
Handled case by case each quarter.
A3
What does our policy say about departing from a method?
Why it mattersA trigger makes a departure a control.
Strong answer · warning sign
Written triggers.
"The controller knows."
B
How a contract change reaches accounting
B1
Who tells accounting a contract changed, and how long does it take?
Why it mattersThis is the gap the example turns on.
Strong answer · warning sign
A named route, measured in days.
An email when someone remembers.
B2
Which clauses change a rate by plan, position or date?
Why it mattersThese become the comparisons to run.
Strong answer · warning sign
A list reviewed by contracting.
"The rate is the rate."
B3
What do we do with an amendment that reaches back into a closed quarter?
Why it mattersCould be a new fact, or an old one.
Strong answer · warning sign
A documented analysis with auditors.
Booked and moved on.
C
Feeds, lags and tie-outs
C1
Which feeds are late or incomplete at close?
Why it mattersSets what must be estimated.
Strong answer · warning sign
A table by feed and day.
Assumed fine.
C2
Do we fit lag curves, and over how long?
Why it mattersA curve needs enough quarters, and old ones may not fit.
Strong answer · warning sign
A stated history and a yearly review.
Last quarter times a factor.
C3
How do we show each report used is complete and accurate?
Why it mattersAuditors test this.
Strong answer · warning sign
Tie-outs kept per close.
Rebuilt on request.
D
Sign-off, auditors and what stays with people
D1
What is our review threshold, and who decides above it?
Why it mattersBecomes a setting.
Strong answer · warning sign
Written, with evidence.
Unwritten.
D2
Which of our true-ups were errors in hindsight?
Why it mattersAn honest list tells you where to start.22
Strong answer · warning sign
Reviewed with auditors.
"They were all estimates."
D3
Which steps would we never let software do without a person?
Why it mattersTells you where signatures belong.
Strong answer · warning sign
Choosing assumptions, signing, sending to auditors.
In shortThe questions finance teams and newcomers search for, each answered on its own.
What are gross-to-net accruals?
Gross-to-net accruals are a drug maker's estimates of the rebates, chargebacks, fees, discounts and returns it will owe on a period's sales. They reduce gross sales at list price to the net revenue the company reports. They are estimates because most of the bills arrive weeks or months after the sale.
What does gross-to-net mean in pharma?
Gross-to-net, or GTN, is the gap between a drug's sales at list price and what the maker keeps after rebates, discounts, fees and returns. Drug Channels Institute estimated it at $416 billion for US brand-name drugs in 2025.1 Three large makers that disclosed an average discount from list averaged 51.7%.1
What is a gross-to-net bridge?
A gross-to-net bridge, or waterfall, shows gross sales stepping down through each deduction to net revenue for one period. Finance teams use it to see which program moved net price and to explain results. It works best when each step can be opened to the schedule behind it.
How do you calculate a rebate accrual?
A commercial rebate accrual is usually eligible units times list price times the contract rate. A Medicaid accrual is usually dispensed units times the Medicaid share of units times the unit rebate amount. Each factor should trace to a file or a clause, and channel inventory has to be taken out of units sold.
Are rebates variable consideration under ASC 606?
Yes. Rebates, chargebacks, discounts and returns are variable consideration, so the amount is estimated at the time of sale.21,19 A company includes revenue only to the extent it is probable that a significant reversal will not occur, weighing how likely and how large a reversal would be.18 The estimate is updated at each reporting date.
What is a true-up in gross-to-net?
A true-up is an adjustment to an earlier period's estimate, recorded when the actual bill or new information arrives. It affects revenue in the current period. One large maker reports $485 million of reductions to earlier provisions in 2025.16 True-ups from new information are normal, and a pattern in one direction is a reason to revisit the method.
Is a missed contract amendment an error or a change in estimate?
It may be an error. Accounting guidance treats an oversight or misuse of facts that existed when the statements were prepared as an error, and new information as a change in estimate.22 A signed amendment sitting in the contract system at the balance date is hard to call new. Discuss specific cases with your auditors, since materiality is a separate question.62
Why are rebate reserves a critical audit matter?
A critical audit matter relates to material accounts and involves especially challenging, subjective or complex auditor judgment.52 Rebate accruals are often both: large, and built on assumptions about payer mix, lags and channel inventory.16 Many drug makers' fiscal 2025 audit reports describe them this way.
How long does it take to settle a Medicaid rebate?
States have 60 days after a quarter to report utilization, and the maker has 30 days after receipt to pay, with interest starting after 37 calendar days from the postmark.5,46 Real lags vary by state and disputes. Filings describe delays of several months, and we found no public average, so measure yours from payment history.45
How do you accrue for Medicare negotiated price refunds?
From January 1, 2026, makers of selected drugs must make the negotiated price available to pharmacies. The default refund through the Medicare Transaction Facilitator, the federal go-between for pharmacies and makers, is list price less the negotiated price.33 Each refund notice it sends starts a 14-day window.11 With little history, accruals lean on actual claims received plus a stated estimate of what is still to come.
What is the difference between gross-to-net accruals and rebate validation?
Rebate validation checks a payer's invoice before you pay it. Gross-to-net accrual estimates what you will owe before an invoice exists, across every program. Validated invoices feed the true-up and the payment history, so the two jobs share data and a contract record.
What data do you need for gross-to-net accruals?
Sales from the ERP, wholesaler inventory and resale data (EDI 852 and 867), contracts and amendments, price and government pricing files, state invoices, PBM utilization files, Medicare refund claims, chargeback lines, payment history and last quarter's memo. Show each report used is complete and accurate, because auditors test that.
Can AI do gross-to-net accruals?
AI can read contracts, tie feeds, rebuild schedules, propose causes and draft memos with citations. It should not choose an assumption or sign a number. Test it on a closed quarter with planted errors, and agree on the evidence with your auditors first. We found no independent benchmark of its accuracy on this work.
Is a gross-to-net system subject to 21 CFR Part 11?
Part 11 and GxP (good-practice quality) rules cover regulated development and manufacturing records, and a revenue reserve is financial reporting. The relevant framework is internal control over financial reporting under Sarbanes-Oxley section 404.40 A vendor can offer controls that support your compliance, such as signatures and audit trails. No software is "certified" for these rules.
23 · One-page summary
The gross-to-net close on one page: seven steps, the rules as of 2026, your score and 14 terms
Print this page
In shortThe whole guide on one screen: the method, the rules as of November 2026, the readiness questions and the terms.
The method
Tie every feed to the ERP and general ledger; stop if totals differ.
Compare every contract term in force in the quarter with the rate in the schedule.
Rebuild each program: units, price, rate, share, inventory, each with a source.
Run a second estimate from payment history; state the history length.
Roll forward each reserve; look back at old estimates against what was paid.
Route variances above a written threshold; a person decides, with a reason.
Sign; write the memo from signed decisions; answer auditors with evidence.
Readiness: score 0–2 on eight questions: 0–6 explore · 7–11 pilot · 12–16 implement.
As of November 2026: Medicaid rebate cap ended January 1, 2024 · Manufacturer Discount Program from January 1, 2025 · negotiated Medicare prices from January 1, 2026, 15 more January 1, 2027 · GLOBE final, set to start January 1, 2027, challenged in court; GUARD not published · revised 340B rebate pilot set for January 1, 2027, under challenge · Part D PBM pay delinked from drug prices from January 1, 2028.
14 terms
Gross-to-net
The gap between list-price sales and what a maker keeps.
Accrual
This period's estimated deduction, taken from revenue.
Reserve
The balance owed at a date.
True-up
A later change to an earlier period's estimate.
Roll-forward
Opening reserve, plus provision and true-ups, less payments.
Lag curve
How much of a quarter's liability is paid by each later quarter.
Variable consideration
The part of a price that can change after the sale, under ASC 606.
Constraint
Include revenue only where a significant reversal is not probable.
WAC
Wholesale acquisition cost: the list price.
AMP
Average manufacturer price, reported to Medicaid.
Unit rebate amount
The Medicaid rebate per unit for a drug and quarter.
MFP
Maximum fair price: Medicare's negotiated price.
Critical audit matter
A material matter involving especially challenging auditor judgment, named in the report.
PBC list
"Provided by client": the auditor's request list.
24 · Sources
Sources
Accessed November 2026. Regulatory status statements are as of November 2026.
Drug Channels Institute (A. Fein), "2025 Gross-to-Net Realities at Eight" manufacturers, July 2026. drugchannels.net
Bristol Myers Squibb Company, Form 10-K for 2025, revenue note: reconciliation of gross product sales to net product sales. sec.gov
Bristol Myers Squibb Company, Form 10-K for 2025: management discussion and the auditor's critical audit matter, read only in excerpts of the filing, because we could not open those parts on sec.gov. sec.gov
CMS, "Medicare Inflation Rebate Program", read November 3, 2026. cms.gov
42 USC 1396r-8, Payment for covered outpatient drugs (Social Security Act section 1927), current text. law.cornell.edu
Informa Connect, Pharma/Biotech GTN Summit Industry Benchmarking Report, created July 2026: audience polls at the 2025 summit; sample size not stated. informaconnect.com
42 CFR 447.509, Medicaid drug rebates, current text. law.cornell.edu
42 USC 1395w-114c, Manufacturer discount program, current text. law.cornell.edu
CMS, Medicare Drug Price Negotiation Program, "Selected Drugs and Negotiated Prices", current page. cms.gov
Centers for Medicare & Medicaid Services, Medicare Transaction Facilitator User Guide, Version 1.0, June 9, 2025. cms.gov
CMS, "Fact Sheet: Medicare Part B Inflation Rebates for Calendar Year 2025", June 2026. cms.gov
42 USC 256b, Limitation on prices of drugs purchased by covered entities (Public Health Service Act section 340B), current text. law.cornell.edu
Healthcare Distribution Alliance, "EDI 844 Product Transfer Account Adjustment", published 2026. hda.org
Healthcare Distribution Alliance, "EDI 849 Response to Product Transfer Account Adjustment", published 2020. hda.org
Bristol Myers Squibb Company, Form 10-K for 2025, revenue note: gross-to-net text and changes in estimates for prior periods. sec.gov
Bristol Myers Squibb Company, Form 10-Q for the quarter ended September 30, 2026: revenue note, gross product sales and gross-to-net adjustments, our arithmetic; the reason read only in an excerpt of the filing. sec.gov
Financial Accounting Standards Board, Accounting Standards Update 2014-09, Section A, paragraphs 606-10-32-8, 32-11 and 32-12 as issued. storage.fasb.org
EisnerAmper (A. Rose), "ASC 606: Challenges for Life Sciences Organizations", August 1, 2024. eisneramper.com
Eli Lilly and Company, Form 10-K for 2025, revenue note. sec.gov
RevenueHub (BYU School of Accountancy), "Variable consideration constraint", quoting ASC 606-10-32-11 and 32-12. revenuehub.org
BDO, "Accounting Changes and Error Corrections", September 17, 2024, on ASC 250. bdo.com
Supernus Pharmaceuticals, Inc., Form 10-K for 2023, read only in excerpts of the filing. sec.gov
US Securities and Exchange Commission, Litigation Release No. 18822, on the final judgment against Bristol-Myers Squibb Company (complaint filed August 4, 2004). sec.gov
US Securities and Exchange Commission, Release 34-86269, July 1, 2019, order approving PCAOB AS 2501, Auditing Accounting Estimates. sec.gov
CMS Innovation Center, "GENEROUS Model", page modified October 14, 2026. cms.gov
Public Law 119-75, Consolidated Appropriations Act, 2026, February 3, 2026, sections 6224 and 6702. govinfo.gov
Gibson Dunn, "The GLOBE Final Rule: A Narrow Model that May Be a Bellwether for Most Favored Nation Pricing", October 14, 2026, on 91 FR 62936. gibsondunn.com
Health Resources and Services Administration, "Notice Regarding 340B Rebate Model Pilot Program", 91 FR 48883, August 3, 2026, FR Doc. 2026-15633. govinfo.gov
American Hospital Association, "AHA urges court to reject drug industry intervention in 340B rebate program case", October 21, 2026. aha.org
Office of Information and Regulatory Affairs, regulatory reviews under way, list of November 3, 2026: GUARD model final rule, CMS-5546, RIN 0938-AV74, received June 15, 2026. reginfo.gov
AJMC, report of PhRMA's suit in the US District Court for the District of Columbia, October 8, 2026. ajmc.com
Centers for Medicare & Medicaid Services, Medicare Transaction Facilitator: Manufacturer Frequently Asked Questions, August 2025. cms.gov
King & Spalding, "Medicare and Medicaid Demos Seek to Impose MFN Pricing: An Overview of GENEROUS, GLOBE and GUARD", December 29, 2025. kslaw.com
American Hospital Association, "AHA expresses support for House bill that would delay 340B rebate model", October 15, 2026, on H.R. 10770. aha.org
Centers for Medicare & Medicaid Services, proposed rule CMS-4214-P, 91 FR 66408, October 20, 2026. govinfo.gov
Federal Trade Commission, "Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)", case page, File No. 221 0114, last updated July 14, 2026, read November 3, 2026. ftc.gov
FDA, "Computer Software Assurance for Production and Quality Management System Software", final guidance, February 2026. fda.gov
European Commission and PIC/S, draft EU GMP Annex 22, consultation July 7 to October 7, 2025; EudraLex Volume 4 listed no Annex 22 on November 3, 2026. picscheme.org
15 USC 7262, Management assessment of internal controls (Sarbanes-Oxley Act section 404), current text. law.cornell.edu
X12, example of an 852 Product Activity Data transaction, read only in an excerpt. x12.org
TrueCommerce, "EDI 867: Product Transfer and Resale Report", read only in an excerpt. truecommerce.com
IQVIA (L. Campbell, H. Lopez, S. Dhawan), "Deconstructing Managed Care Rebate Processing Challenges", white paper, 2023. iqvia.com
42 CFR 447.510, Requirements for manufacturers, current text. law.cornell.edu
Acadia Pharmaceuticals Inc., Form 10-K for 2025, risk factors. sec.gov
Centers for Medicare & Medicaid Services, "Interest Calculation for Late Rebate Payments", page updated June 10, 2026. medicaid.gov
Eli Lilly and Company, Form 10-K for 2025: roll-forward of U.S. sales rebate, discount and return liabilities, and sensitivity. sec.gov
M. Faddoul (Crowe), "Why Gross-to-Net Internal Controls Should Be a Launch Priority for Specialty Pharma Companies", Pharmaceutical Executive, July 27, 2026. pharmexec.com
Bristol-Myers Squibb Company, Form 8-K exhibit 99.1, press release of March 10, 2003, Appendix 1, note 3. sec.gov
Insys Therapeutics, Inc., Form 8-K, event date March 30, 2017, Item 4.02. sec.gov
Eagle Pharmaceuticals, Inc., Form 8-K, signed December 15, 2023, Item 4.02. sec.gov
US Securities and Exchange Commission, Release 34-81916, October 23, 2017, order approving PCAOB AS 3101, including critical audit matters. sec.gov
Pfizer Inc., Form 10-K for 2025, auditor's report, read only in excerpts of the filing. sec.gov
Indivior Pharmaceuticals, Inc., Form 10-K for 2025, auditor's report, read only in excerpts of the filing. sec.gov
TG Therapeutics, Inc., Form 10-K for 2025, auditor's report, read only in excerpts of the filing. sec.gov
Tarsus Pharmaceuticals, Inc., Form 10-K for 2025, auditor's report, read only in excerpts of the filing. sec.gov
BeOne Medicines Ltd., Form 10-K for 2025, auditor's report, read only in excerpts of the filing. sec.gov
ADC Therapeutics SA, Form 10-K for 2025, auditor's report, read only in excerpts of the filing. sec.gov
Harrow, Inc., Form 10-K for 2025, auditor's report, read only in excerpts of the filing. sec.gov
Liquidia Corporation, Form 10-K for 2025, auditor's report, read only in excerpts of the filing. sec.gov
Zoetis Inc., Form 10-K for 2025, auditor's report, read only in excerpts of the filing. sec.gov
US Securities and Exchange Commission, Staff Accounting Bulletin No. 99, Materiality. sec.gov
Drug Channels Institute, "Gross-to-Net Bubble Hits $356B in 2024, But Growth Slows to 10-Year Low", July 15, 2025. drugchannels.net
Pharmaceutical Commerce, "Life Sciences Leaders Report Rising Gross-to-Net Complexity", February 17, 2026, on the Model N survey by Dimensional Research (429 leaders). pharmaceuticalcommerce.com
Model N, "The state of pharma revenue in 2026", infographic from its 2026 State of Revenue Report (seller's research). modeln.com
FDA, "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products", draft guidance, January 2025. fda.gov
B. Strickland, "COSO creates audit-ready guidance for governing generative AI", Journal of Accountancy, February 26, 2026. journalofaccountancy.com
42 CFR 447.505, Determination of best price, current text. law.cornell.edu
HHS, "Annual Civil Monetary Penalties Inflation Adjustment", 91 FR 3665, January 28, 2026 (45 CFR 102.3); HHS later announced no adjustment for 2026 (FR Doc. 2026-21524). govinfo.gov
Next step
See it on your own quarter-end close.
Explore the solution, or bring a past quarter of your own contracts, feeds and schedules, and we will rebuild the reserves with you, every assumption beside its clause, file or curve.
We use essential cookies to make this site work, and cookieless, anonymised analytics to understand how it's used. "Accept all" also turns on Google Analytics, which sets cookies. Privacy policy